This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven.
Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.
AUA/IPSS score is ≤ 15.
ECOG performance status is ≤2 (or Karnofsky score is ≥60%).
Patient has baseline grade ≥3 GI or GU toxicity
Patient has had prior overlapping pelvic radiotherapy.
Patient has had prior transurethral resection of the prostate, prostate HIFU, or cryoablation.
Patient has node positive prostate cancer.